Rating Change
Guggenheim reiterated its Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) on November 16, 2026.
Guggenheim reiterated its Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) on November 16, 2026.

At publication ·
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) · reiterate
At a glance
Guggenheim reiterated its Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) on November 16, 2026.
Zevra Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $9.64 with a market capitalization of $472.3M. The stock has declined 3.4% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zevra Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 16, 2026 | Guggenheim | Buy | N/A |
| Nov 13, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Nov 13, 2026 | BTIG | Buy | N/A |
| Aug 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 07, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ZVRA Stock Page
A rating of Buy from Guggenheim reflects the analyst's outlook on Zevra Therapeutics, Inc. (NASDAQ:ZVRA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZVRA forecast page.
Current market data
NASDAQ · ZVRA
$8.76
Down: -$0.31 · -3.42%
Live quote updated
Keep reading
price ·
analyst ·
analyst ·
earnings ·